3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester (BioDeep_00000184662)

   

human metabolite blood metabolite


代谢物信息卡片


4-[({1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl}(hydroxy)methylidene)amino]cyclohexane-1-carboxylate

化学式: C29H41NO7 (515.2882876000001)
中文名称: 坎沙曲
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COCCOCC(CC1(CCCC1)C(=O)NC1CCC(CC1)C(O)=O)C(=O)OC1=CC2=C(CCC2)C=C1
InChI: InChI=1S/C29H41NO7/c1-35-15-16-36-19-23(27(33)37-25-12-9-20-5-4-6-22(20)17-25)18-29(13-2-3-14-29)28(34)30-24-10-7-21(8-11-24)26(31)32/h9,12,17,21,23-24H,2-8,10-11,13-16,18-19H2,1H3,(H,30,34)(H,31,32)

描述信息

D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents
D004791 - Enzyme Inhibitors > D011480 - Protease Inhibitors

同义名列表

5 个代谢物同义名

4-[({1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentyl}(hydroxy)methylidene)amino]cyclohexane-1-carboxylate; 4-{1-[3-(2,3-dihydro-1H-inden-5-yloxy)-2-[(2-methoxyethoxy)methyl]-3-oxopropyl]cyclopentaneamido}cyclohexane-1-carboxylic acid; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoic acid 5-indanyl ester; 3-(1-((4-Carboxycyclohexyl)carbamoyl)cyclopentyl)-2-(2-methoxyethoxymethyl)propanoate 5-indanyl ester; candoxatril



数据库引用编号

5 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Johanne A Windeløv, Nicolai J Wewer Albrechtsen, Rune E Kuhre, Sara L Jepsen, Daniel Hornburg, Jens Pedersen, Elisa P Jensen, Katrine D Galsgaard, Marie Winther-Sørensen, Anne Ørgaard, Carolyn F Deacon, Matthias Mann, Hannelouise Kissow, Bolette Hartmann, Jens J Holst. Why is it so difficult to measure glucagon-like peptide-1 in a mouse?. Diabetologia. 2017 10; 60(10):2066-2075. doi: 10.1007/s00125-017-4347-7. [PMID: 28669086]
  • Yoav Eizenberg, Ehud Grossman, Edna Peleg, Zehava Shabtai, Yehonatan Sharabi. Neutral endopeptidase inhibitor versus angiotensin converting enzyme inhibitor in a rat model of the metabolic syndrome. Journal of the American Society of Hypertension : JASH. 2014 Apr; 8(4):227-31. doi: 10.1016/j.jash.2014.01.006. [PMID: 24560177]
  • Laxminarayan G Hegde, Cecile Yu, Travis Renner, Harold Thibodeaux, Scott R Armstrong, Timothy Park, Madhavi Cheruvu, Rachael Olsufka, Erik R Sandvik, Cassie E Lane, Joe Budman, Craig M Hill, Uwe Klein, Sharath S Hegde. Concomitant angiotensin AT1 receptor antagonism and neprilysin inhibition produces omapatrilat-like antihypertensive effects without promoting tracheal plasma extravasation in the rat. Journal of cardiovascular pharmacology. 2011 Apr; 57(4):495-504. doi: 10.1097/fjc.0b013e318210fc7e. [PMID: 21297495]
  • Richard J Mitchell, Rachelle Christian, Heather Hughes, Asadh Miah, Donald K Walker. The application of fully automated on-line solid phase extraction in bioanalysis. Journal of pharmaceutical and biomedical analysis. 2010 May; 52(1):86-92. doi: 10.1016/j.jpba.2009.11.002. [PMID: 20047815]
  • Mohammad Newaz, Zivar Yousefipour, Adebayo Oyekan. Natriuretic and renoprotective effect of chronic oral neutral endopeptidase inhibition in acute renal failure. Renal failure. 2010 Jan; 32(3):384-90. doi: 10.3109/08860221003611745. [PMID: 20370457]
  • Fernando L Martin, Tracy L Stevens, Alessandro Cataliotti, John A Schirger, Daniel D Borgeson, Margaret M Redfield, Andreas Luchner, John C Burnett. Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. Kidney international. 2005 May; 67(5):1723-30. doi: 10.1111/j.1523-1755.2005.00269.x. [PMID: 15840018]
  • E Kostova, E Jovanoska, D Zafirov, K Jakovski, V Maleska, M Slaninka-Miceska. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats. Bratislavske lekarske listy. 2005; 106(12):407-11. doi: . [PMID: 16642666]
  • Ramona Trebbien, Letty Klarskov, Mette Olesen, Jens J Holst, Richard D Carr, Carolyn F Deacon. Neutral endopeptidase 24.11 is important for the degradation of both endogenous and exogenous glucagon in anesthetized pigs. American journal of physiology. Endocrinology and metabolism. 2004 Sep; 287(3):E431-8. doi: 10.1152/ajpendo.00353.2003. [PMID: 15126240]
  • Mohammad A Newaz, Zivar Yousefipour, Hantz Hercule, Luan Truong, Adebayo Oyekan. Chronic endopeptidase inhibition in DOCA-salt hypertension: mechanism of cardiovascular protection. Clinical and experimental hypertension (New York, N.Y. : 1993). 2003 Aug; 25(6):335-47. doi: 10.1081/ceh-120023543. [PMID: 12940471]
  • M Haloui, D Messika-Zeitoun, L Louedec, M Philippe, J B Michel. Potentiation of urinary atrial natriuretic peptide interferes with macula densa function. Cardiovascular research. 2001 Aug; 51(3):542-52. doi: 10.1016/s0008-6363(01)00298-x. [PMID: 11476744]
  • J F Arnal, C Castano, E Maupas, A Mugniot, B Darblade, P Gourdy, J B Michel, F Bayard. Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice. Atherosclerosis. 2001 Apr; 155(2):291-5. doi: 10.1016/s0021-9150(00)00565-7. [PMID: 11254898]
  • T Kuro, A Okahara, M Nose, T Ikuse, Y Matsumura. Effects of SA7060, a novel dual inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on deoxycorticosterone acetate-salt-induced hypertension in rats. Biological & pharmaceutical bulletin. 2000 Jul; 23(7):820-5. doi: 10.1248/bpb.23.820. [PMID: 10919359]
  • D B Northridge, D E Newby, E Rooney, J Norrie, H J Dargie. Comparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failure. American heart journal. 1999 Dec; 138(6 Pt 1):1149-57. doi: 10.1016/s0002-8703(99)70082-7. [PMID: 10577447]
  • A S Westheim, P Bostrøm, C C Christensen, H Parikka, E O Rykke, L Toivonen. Hemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failure. Journal of the American College of Cardiology. 1999 Nov; 34(6):1794-801. doi: 10.1016/s0735-1097(99)00435-0. [PMID: 10577572]
  • K Yoshida, M Kanazawa, D J Casley, A Katopothis, C I Johnston. Inhibition of kidney neutral endopeptidase after administration of the neutral endopeptidase inhibitor candoxatril: quantitation by autoradiography. Journal of cardiovascular pharmacology. 1998 Nov; 32(5):702-8. doi: 10.1097/00005344-199811000-00004. [PMID: 9821842]
  • K Yoshida, M Yasujima, D J Casley, C I Johnston. Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction. Japanese circulation journal. 1998 Sep; 62(9):680-6. doi: 10.1253/jcj.62.680. [PMID: 9766707]
  • B Kaye, C J Brearley, N J Cussans, M Herron, M J Humphrey, A R Mollatt. Formation and pharmacokinetics of the active drug candoxatrilat in mouse, rat, rabbit, dog and man following administration of the prodrug candoxatril. Xenobiotica; the fate of foreign compounds in biological systems. 1997 Oct; 27(10):1091-102. doi: 10.1080/004982597240046. [PMID: 9364744]
  • G McDowell, W Coutie, C Shaw, K D Buchanan, A D Struthers, D P Nicholls. The effect of the neutral endopeptidase inhibitor drug, candoxatril, on circulating levels of two of the most potent vasoactive peptides. British journal of clinical pharmacology. 1997 Mar; 43(3):329-32. doi: 10.1046/j.1365-2125.1997.00545.x. [PMID: 9088591]
  • K Kugiyama, S Sugiyama, T Matsumura, Y Ohta, H Doi, H Yasue. Suppression of atherosclerotic changes in cholesterol-fed rabbits treated with an oral inhibitor of neutral endopeptidase 24.11 (EC 3.4.24.11). Arteriosclerosis, thrombosis, and vascular biology. 1996 Aug; 16(8):1080-7. doi: 10.1161/01.atv.16.8.1080. [PMID: 8696950]
  • C D Kimmelstiel, R Perrone, L Kilcoyne, J Souhrada, J Udelson, J Smith, A de Bold, J Griffith, M A Konstam. Effects of renal neutral endopeptidase inhibition on sodium excretion, renal hemodynamics and neurohormonal activation in patients with congestive heart failure. Cardiology. 1996 Jan; 87(1):46-53. doi: 10.1159/000177059. [PMID: 8631044]
  • M Kentsch, W Otter, C Drummer, A Nötges, R Gerzer, G Müller-Esch. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. European journal of clinical pharmacology. 1996; 51(3-4):269-72. doi: 10.1007/s002280050196. [PMID: 9010697]
  • S Ando, M A Rahman, G C Butler, B L Senn, J S Floras. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension (Dallas, Tex. : 1979). 1995 Dec; 26(6 Pt 2):1160-6. doi: 10.1161/01.hyp.26.6.1160. [PMID: 7498988]
  • K B Margulies, P L Barclay, J C Burnett. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation. 1995 Apr; 91(7):2036-42. doi: 10.1161/01.cir.91.7.2036. [PMID: 7895362]
  • G A Sagnella, N D Markandu, M G Buckley, M A Miller, A Blackwood, D R Singer, G A MacGregor. Hormonal and renal responses to neutral endopeptidase inhibition in normal humans on a low and on a high sodium intake. European journal of clinical investigation. 1995 Mar; 25(3):165-70. doi: 10.1111/j.1365-2362.1995.tb01543.x. [PMID: 7781662]
  • T J Wolfensberger, D R Singer, T Freegard, N D Markandu, M G Buckley, G A MacGregor. Evidence for a new role of natriuretic peptides: control of intraocular pressure. The British journal of ophthalmology. 1994 Jun; 78(6):446-8. doi: 10.1136/bjo.78.6.446. [PMID: 8060926]
  • Y Hirata, Y Suzuki, E Suzuki, H Hayakawa, K Kimura, A Goto, M Omata, N Minamino, K Kangawa, H Matsuo. Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors. Journal of hypertension. 1994 Apr; 12(4):367-74. doi: NULL. [PMID: 8064160]
  • Y Hirata, E Suzuki, H Hayakawa, H Matsuoka, T Sugimoto, K Kangawa, H Matsuo. Mechanisms of the natriuretic effects of neutral endopeptidase inhibition in Dahl salt-sensitive and salt-resistant rats. Journal of cardiovascular pharmacology. 1994 Feb; 23(2):283-90. doi: NULL. [PMID: 7511759]
  • T J Tunny, M D Ziesak, R Armstrong, S A Klemm, M Stowasser, W L Finn, R D Gordon. Inhibition of endopeptidase EC 3.4.24.11 by candoxatril lowered blood pressure and increased urinary but not plasma atrial natriuretic peptide in essential hypertension. Journal of hypertension. Supplement : official journal of the International Society of Hypertension. 1993 Dec; 11(5):S222-3. doi: 10.1097/00004872-199312050-00090. [PMID: 8158355]
  • J G Motwani, C C Lang, M J Allen, H F Johnson, A D Struthers. Dose-ranging effects of candoxatril on elimination of exogenous atrial natriuretic peptide in chronic heart failure. Clinical pharmacology and therapeutics. 1993 Dec; 54(6):661-9. doi: 10.1038/clpt.1993.204. [PMID: 8275621]
  • A M Richards, I G Crozier, E A Espiner, T G Yandle, M G Nicholls. Plasma brain natriuretic peptide and endopeptidase 24.11 inhibition in hypertension. Hypertension (Dallas, Tex. : 1979). 1993 Aug; 22(2):231-6. doi: 10.1161/01.hyp.22.2.231. [PMID: 8340158]
  • J E O'Connell, A G Jardine, D L Davies, J McQueen, J M Connell. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man. Clinical science (London, England : 1979). 1993 Jul; 85(1):19-26. doi: 10.1042/cs0850019. [PMID: 8149689]
  • A M Richards, G A Wittert, I G Crozier, E A Espiner, T G Yandle, H Ikram, C Frampton. Chronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin II. Journal of hypertension. 1993 Apr; 11(4):407-16. doi: 10.1097/00004872-199304000-00011. [PMID: 8390508]
  • N Takahashi, Y Kondo, K Kudo, Y Igarashi, O Ito, K Abe. Lack of direct action of atriopeptidase inhibitor on cellular pH regulation in rabbit S2 proximal straight tubules. The Tohoku journal of experimental medicine. 1993 Apr; 169(4):261-70. doi: 10.1620/tjem.169.261. [PMID: 8248916]
  • A M Richards, G A Wittert, E A Espiner, T G Yandle, H Ikram, C Frampton. Effect of inhibition of endopeptidase 24.11 on responses to angiotensin II in human volunteers. Circulation research. 1992 Dec; 71(6):1501-7. doi: 10.1161/01.res.71.6.1501. [PMID: 1423942]
  • T Yandle, M Richards, M Smith, C Charles, J Livesey, E Espiner. Assay of endopeptidase-24.11 activity in plasma applied to in vivo studies of endopeptidase inhibitors. Clinical chemistry. 1992 Sep; 38(9):1785-91. doi: 10.1093/clinchem/38.9.1785. [PMID: 1526015]
  • D Elsner, A Müntze, E P Kromer, G A Riegger. Effectiveness of endopeptidase inhibition (candoxatril) in congestive heart failure. The American journal of cardiology. 1992 Aug; 70(4):494-8. doi: 10.1016/0002-9149(92)91196-b. [PMID: 1386491]
  • E G Bevan, J M Connell, J Doyle, H A Carmichael, D L Davies, A R Lorimer, G T McInnes. Candoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertension. Journal of hypertension. 1992 Jul; 10(7):607-13. doi: . [PMID: 1321186]
  • C C Lang, J G Motwani, W J Coutie, A D Struthers. Clearance of brain natriuretic peptide in patients with chronic heart failure: indirect evidence for a neutral endopeptidase mechanism but against an atrial natriuretic peptide clearance receptor mechanism. Clinical science (London, England : 1979). 1992 Jun; 82(6):619-23. doi: 10.1042/cs0820619. [PMID: 1320540]
  • G A Sagnella, D R Singer, N D Markandu, M G Buckley, G A MacGregor. Is atrial natriuretic peptide-guanosine 3',5' cyclic monophosphate coupling a determinant of urinary sodium excretion in essential hypertension?. Journal of hypertension. 1992 Apr; 10(4):349-54. doi: 10.1097/00004872-199204000-00005. [PMID: 1316400]
  • J E O'Connell, A G Jardine, G Davidson, J M Connell. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension. Journal of hypertension. 1992 Mar; 10(3):271-7. doi: 10.1097/00004872-199203000-00011. [PMID: 1315825]
  • E Suzuki, Y Hirata, H Matsuoka, T Sugimoto, H Hayakawa, T Sugimoto, K Kangawa, N Minamino, H Matsuo. Characterization of atrial natriuretic peptide in urine from rats treated with a neutral endopeptidase inhibitor. Biochemical and biophysical research communications. 1992 Feb; 182(3):1270-6. doi: 10.1016/0006-291x(92)91869-r. [PMID: 1531753]
  • D R Singer, N D Markandu, M G Buckley, M A Miller, G A Sagnella, G A MacGregor. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension. Hypertension (Dallas, Tex. : 1979). 1991 Dec; 18(6):798-804. doi: 10.1161/01.hyp.18.6.798. [PMID: 1835959]
  • A M Richards, G Wittert, E A Espiner, T G Yandle, C Frampton, H Ikram. Prolonged inhibition of endopeptidase 24.11 in normal man: renal, endocrine and haemodynamic effects. Journal of hypertension. 1991 Oct; 9(10):955-62. doi: NULL. [PMID: 1658138]
  • C C Lang, J Motwani, W J Coutie, A D Struthers. Influence of candoxatril on plasma brain natriuretic peptide in heart failure. Lancet (London, England). 1991 Jul; 338(8761):255. doi: 10.1016/0140-6736(91)90397-8. [PMID: 1676808]
  • E P Kromer, D Elsner, H W Kahles, G A Riegger. Effects of atriopeptidase inhibitor UK 79300 on left ventricular hydraulic load in patients with congestive heart failure. American journal of hypertension. 1991 May; 4(5 Pt 1):460-3. doi: 10.1093/ajh/4.5.460. [PMID: 1829902]
  • M Richards, E Espiner, C Frampton, H Ikram, T Yandle, M Sopwith, N Cussans. Inhibition of endopeptidase EC 24.11 in humans. Renal and endocrine effects. Hypertension (Dallas, Tex. : 1979). 1990 Sep; 16(3):269-76. doi: 10.1161/01.hyp.16.3.269. [PMID: 2144260]